Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01240161 : Personalized Translational Platform for Biomarker Discovery in Brain Tumors
PhaseN/A
AgesMin: 18 Years Max: 85 Years
Eligibility
Inclusion Criteria:

- Newly diagnosed or suspected high grade glioma ? 1cm in diameter on postoperative
anatomic imaging (contrast MRI), prior to initiation of chemoXRT

- Anticipated survival ?6 months

- Able to give informed consent

- Capable of undergoing MRI and PET scans without the need for sedation or general
anesthesia

- Male or Female

Exclusion Criteria:

- Prior radiation therapy and chemotherapy to the brain

- Active intracranial infection or nonglial brain mass.

- Recent large intracranial hemorrhage (<1 month)

- Expected survival <6 months

- Pregnant or nursing

- Renal failure

- Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging
visits.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01240161      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740